Evidence map›Paper›PMID 12454801›Full record

ArticleAmerican journal of human genetics2002

The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.

W D Foulkes, I Thiffault, S B Gruber, M Horwitz, N Hamel, C Lee, J Shia, A Markowitz, A Figer, E Friedman and 23 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 132 citations in OpenAlex.

  1. Breast-Ovarian Hereditary Cancer Syndrome: BeyondCurrent oncology (Toronto, Ont.) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Novel loci for Alzheimer's disease identified by a genome-wide association study in Ashkenazi Jews.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Frontiers in oncology · 2018
    Article
  16. MSH2 Loss in Primary Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Article
  17. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 14 institutions in 6 countries.

W D FoulkesDepartment of Medicine, Sir Mortimer B Davis-Jewish General Hospital, Montreal, Quebec, Canada, H3G 1A4. william.foulkes@mcgill.ca
I Thiffault
S B Gruber
M Horwitz
N Hamel
C Lee
J Shia
A Markowitz
A Figer
E Friedman
D Farber
C M T Greenwood
J D Bonner
K Nafa
T Walsh
V Marcus
L Tomsho
J Gebert
F A Macrae
C L Gaff
B Bressac-De Paillerets
P K Gregersen
J N Weitzel
P H Gordon
E MacNamara
M-C King
H Hampel
A De La Chapelle
J Boyd
K Offit
G Rennert
G Chong
N A Ellis
Memorial Sloan Kettering Cancer Center · USMcGill University Health Centre · CAUniversity of Michigan–Ann Arbor · USUniversity of Washington Medical Center · USCancer Genetics (United States) · USJewish General Hospital · CACancer Clinic · USCity of Hope · USHeidelberg University · DEInstitut Gustave Roussy · FRMcGill University · CASheba Medical Center · ILTel Aviv Sourasky Medical Center · ILVictorian Clinical Genetics Services · AU

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
MOLECULAR EPIDEMIOLOGY OF COLORECTAL CANCERR01CA081488 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GRUBER, STEPHEN B · 1999 to 2008
$9.2M
COMPLETE VARIANT PROFILING OF ALL KNOWN BREAST CANCER GENESR01CA175716 · NCI · UNIVERSITY OF WASHINGTON · PI KING, MARY-CLAIRE, WALSH, TOMAS D · 2013 to 2017
$3.1M
INCIDENCE AND MOLECULAR SCREENING FOR HEREDITARY CANCERR01CA067941 · NCI · OHIO STATE UNIVERSITY · PI DE LA CHAPELLE, ALBERT · 2000 to 2004
$2.9M
NATURAL HISTORY AND INCIDENCE OF HEREDITARY COLON CANCERU01CA067941 · NCI · UNIVERSITY OF HELSINKI · PI DE LA CHAPELLE, ALBERT · 1996 to 1999
–
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA067941NCI NIH HHS R01 CA081488NCI NIH HHS R01 CA175716NCI NIH HHS R01 CA81488NCI NIH HHS U01 CA067941
6 · The paper itself

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is caused by mutations in the mismatch-repair genes. We report here the identification and characterization of a founder mutation in MSH2 in the Ashkenazi Jewish population. We identified a nucleotide substitution, MSH2*1906G-->C, which results in a substitution of proline for alanine at codon 636 in the MSH2 protein. This allele was identified in 15 unrelated Ashkenazi Jewish families with HNPCC, most of which meet the Amsterdam criteria. Genotype analysis of 18 polymorphic loci within and flanking MSH2 suggested a single origin for the mutation. All colorectal cancers tested showed microsatellite instability and absence of MSH2 protein, by immunohistochemical analysis. In an analysis of a population-based incident series of 686 Ashkenazi Jews from Israel who have colorectal cancer, we identified 3 (0.44%) mutation carriers. Persons with a family history of colorectal or endometrial cancer were more likely to carry the mutation than were those without such a family history (P=.042), and those with colorectal cancer who carried the mutation were, on average, younger than affected individuals who did not carry it (P=.033). The mutation was not detected in either 566 unaffected Ashkenazi Jews from Israel or 1,022 control individuals from New York. In hospital-based series, the 1906C allele was identified in 5/463 Ashkenazi Jews with colorectal cancer, in 2/197 with endometrial cancer, and in 0/83 with ovarian cancer. When families identified by family history and in case series are included, 25 apparently unrelated Ashkenazi Jewish families have been found to harbor this mutation. Although this pathogenic mutation is not frequent in the Ashkenazi Jewish population (accounting for 2%-3% of colorectal cancer in those whose age at diagnosis is <60 years), it is highly penetrant and accounts for approximately one-third of HNPCC in Ashkenazi Jewish families that fulfill the Amsterdam criteria.

Indexed as

DNA-Binding ProteinsFounder EffectGenetic Predisposition to DiseaseAlanineCase-Control StudiesChromosomes, Human, Pair 2Colorectal Neoplasms, Hereditary NonpolyposisCrystallography, X-RayFemaleGene FrequencyHaplotypesHeterozygoteHumansIsraelJewsMaleAlanineDNA-Binding ProteinsMSH2 protein, humanMutS Homolog 2 ProteinProlineProto-Oncogene Proteins

Identifiers

PMID12454801
PMCPMC420003
OpenAlexW1974807162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.